Outline of the problem of therapeutic efficacy indices, 2: Description of the indices;Apercu sur la problematique des indices d'efficacite therapeutique, 2: Description des indices

Therapie

Volumn 54, Issue 3, 1999, Pages 309-314

  Boissel, Jean Pierre ^a   Buyse, Marc ^a   Cucherat, Michel ^a   Boutitie, Florent ^a   Gueyffier, F Francois ^a   Chatellier, Gilles ^a   Li, Wei ^a   Nony, Patrice ^a   Haugh, Margaret ^a   Mignot, Gilles ^a   Leizorovicz, Alain ^a   Strang, Nigel ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Absolute benefit; Computing; Definition; Efficacy indices; Odds ratio; Relative risk

Indexed keywords

OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; THERAPY; ARTICLE; CLINICAL PROTOCOL; HUMAN; RISK; TREATMENT OUTCOME;

CLINICAL PROTOCOLS; HUMANS; ODDS RATIO; RISK; TREATMENT OUTCOME;

EID: 0033127081     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Boissel JP, Cucherat M, Gueyffier F et al. Aperçu sur la problématique des indices d'efficacité thérapeutique, 1: Eléments de la problématique. Therapie 1999; 54: 203-207.
2. Boissel JP, Cucherat M, Li et al. et le Groupe d'Etude des Indices d'Efficacité. Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: Comparaison des indices et utilisation. Therapie 1999; 54(4).
3. Boissel JP, Cucherat M, Chatellier G et al. Aperçu sur la problématique des indices d'efficacité thérapeutique, 4: Expression de l'efficacité lorsque la maladie sous-jacente ne guérit pas. Therapie 1999; 54(5).
4. Woolf B. On estimating the relation between blood group and disease. Ann Hum Gen 1955; 19: 251-253.
5. Cucherat M. La méta-analyse des essais thérapeutiques. Paris: Masson, 1997.
6. Sackett DL, Deeks JJ, Altman DG. Down with odds ratio. Evidence Based Medicine 1996; 1: 164-166.
7. Decks JJ, Altman DG, Dooley G, Sackett DLS. Choosing an appropriate dichotomous measure for meta-analysis: empirical evidence of the appropriateness of the odds ratio and relative risk. Controlled Clin Trials 1997; 18: 84S-85S.
8. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in metaanalysis. BMJ 1996; 313: 735-738.
9. The INDANA (INdividual Data Analysis of Antihypertensive intervention trials) Project Collaborators: Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997; 126: 761-767.
10. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-1733.
11. Chatelier G, Zapletal E, Lemaitre D et al. The number to treat: a clinically useful nomogram in its proper context. BMJ 1996; 312: 426-429.
12. Boissel JP. Note sur la nécessaire définition des objectifs thérapeutiques pour une démarche de prescription optimisée. Therapie 1996; 51: 287-289.
13. Wei L, Boissel JP, Boutitie F et al. Identification and prediction of responders to a therapy: a model and its preliminary application to actual data. J Epidemiol Biostat 1998; 3: 189-197.